ROR1 and B-cell chronic lymphocytic leukemia: Indeed, an anti-ROR1 monoclonal antibody, namely cirmtuzumab (UC-961), is being tested at the moment alone or in combination with ibrutinib in several phase 1b/2 studies for the treatment of B cell lymphoid malignancies, including CLL [116].